| abstract |
[Problem] To provide chemically modified human growth hormone (rhGH) that can be administered less frequently without increasing the incidence of adipose tissue atrophy. A prodrug conjugate of human growth hormone (hGH) prepared by attaching a self-hydrolyzable (self-cleaving) temporary linker containing a polymer chain, such as polyethylene glycol, and an appropriate pharmaceutical agent. A pharmaceutical composition comprising a dosage form. A pharmaceutical composition having a self-hydrolysis rate of the linker and an in vivo half-life of 10 to 600 hours. Prodrugs and methods for preparing said prodrug conjugates. [Selection] Figure 10 |